Stockscreener 앱 받기
0.8951
4.14%
0.0356
시장 영업 전:
.88
-0.0151
-1.69%
Salarius Pharmaceuticals Inc 주식(SLRX)의 최신 뉴스
Can Salarius Pharmaceuticals Inc. (FP10) stock resist broad market declinesTrend Reversal & Accurate Entry/Exit Alerts - Newser
Why Salarius Pharmaceuticals Inc. stock is a must watch in 2025Weekly Market Summary & Fast Entry High Yield Tips - Newser
Salarius Pharmaceuticals Inc. (SLRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Salarius Pharmaceuticals Inc. stock attractive for income investorsProduct Launch & Daily Entry Point Alerts - Newser
Can Salarius Pharmaceuticals Inc. (FP10) stock sustain breakout momentumJuly 2025 Reactions & AI Powered Market Entry Ideas - Newser
How Salarius Pharmaceuticals Inc. (FP10) stock responds to job market shiftsWeekly Volume Report & Smart Money Movement Alerts - Newser
Salarius Pharmaceuticals, Inc. (SLRX) 7.9% in After-hours: Collaboration with Texas Biomedical Research Institute Sparks Interest - Stocks Telegraph
Salarius Pharmaceuticals' Decoy Unit Partners With Texas Biomed on Flu Inhibitor Testing - MarketScreener
Salarius Pharmaceuticals to collaborate with Texas Biomedical Research Institute on avian flu study - marketscreener.com
SLRX Collaborates with Texas Research Institute for Influenza Te - GuruFocus
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewswire
Will Salarius Pharmaceuticals Inc. stock benefit from infrastructure spending2025 Trade Ideas & AI Forecasted Entry and Exit Points - moha.gov.vn
Is Salarius Pharmaceuticals Inc. stock affected by interest rate hikes2025 Price Action Summary & Consistent Profit Trading Strategies - moha.gov.vn
Hanish of Salarius Pharma buys $3740 in shares By Investing.com - Investing.com South Africa
Hanish of Salarius Pharma buys $3740 in shares - Investing.com India
[Form 4] Salarius Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
What analysts say about Salarius Pharmaceuticals Inc stockDividend Yield Trends & Technical + Fundamental = Smarter Investing - earlytimes.in
Salarius Pharmaceuticals Inc (SLRX) can make a big difference with a little luck - Setenews
[Form 3] Salarius Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
SLRX Stock Institutional Owners - Quiver Quantitative
How Salarius Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - newser.com
Salarius Pharmaceuticals Exec VP Finance, CFO Mark J Rosenblum Acquires 20,000 Shares - TradingView
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol SLRX - MarketScreener
Why Salarius Pharmaceuticals Inc. (FP10) stock stays resilientJuly 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Salarius clarifies Nasdaq listing status, refutes S&P CapIQ error By Investing.com - Investing.com India
Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Down 8.3% – Here’s Why - Defense World
Will Salarius Pharmaceuticals Inc. (FP10) stock benefit from infrastructure bill - newser.com
Ranking Salarius Pharmaceuticals Inc. among high performing stocks via toolsProduct Launch & Stepwise Entry/Exit Trade Alerts - newser.com
When is the best time to exit Salarius Pharmaceuticals Inc.Market Trend Summary & Free Weekly Watchlist of Top Performers - newser.com
What catalysts could drive Salarius Pharmaceuticals Inc. stock higher - newser.com
Applying Elliott Wave Theory to Salarius Pharmaceuticals Inc.Portfolio Profit Report & Low Risk Profit Maximizing Plans - newser.com
[8-K] Salarius Pharmaceuticals, Inc. Reports Material Event | SLRX SEC FilingForm 8-K - Stock Titan
Salarius Pharmaceuticals Says S&P Capital IQ Platform Misreported Nasdaq Status After Merger - marketscreener.com
Salarius Pharmaceuticals (SLRX) Maintains Nasdaq Listing Despite Reporting Error - GuruFocus
Salarius clarifies Nasdaq listing status, refutes S&P CapIQ error - Investing.com
Trend analysis for Salarius Pharmaceuticals Inc. this weekWeekly Risk Report & Advanced Swing Trade Entry Plans - newser.com
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol 'SLRX” - The Manila Times
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - marketscreener.com
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform - GlobeNewswire
1.10%
1.10%
자본화:
|
볼륨(24시간):